Delivery Order SPE2DR25D2018-SPE2DR26FZ1A9
- Not listed
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at approximately $10,000 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pens on January 12, 2026, with an ultimate completion date of January 13, 2026. The contract was competitively awarded with no set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's parent company Cencora, Inc.'s...
- The Defense Logistics Agency awarded a $17,927.70 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound 12.5 mg/0.5 ml pens on January 28, 2026, with a completion date of January 29, 2026. This non-set-aside competitive award represents a small task order for the diabetes medication delivered to the place of performance in Conshohocken, Pennsylvania. The award is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,994.94 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injectables. The contract was awarded on January 21, 2026, with an ultimate completion date of January 22, 2026, and represents a firm fixed-price procurement with no set-aside designation. The product will be delivered to the company's location in Conshohocken, Pennsylvania. This delivery order is executed under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order valued at $14,328.59 to AmerisourceBergen Drug Corp for the supply of Zepbound 10 mg/0.5 ml pen (0.5 ml) with a completion date of January 9, 2026. This non-set-aside contract was awarded on a firm fixed-price basis and represents a competitively awarded delivery order under AmerisourceBergen's existing pharmaceutical supply arrangements. The place of performance is located in Conshohocken, Pennsylvania, where the company maintains its...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $31,358.72 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectors on December 8, 2025, with an ultimate completion date of December 9, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's Conshohocken, Pennsylvania facility. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency (DLA) Medical Supply Chain awarded a $17.1K delivery order to AmerisourceBergen Drug Corp on September 19, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pens with a completion date of September 22, 2025. This is a firm fixed-price, non-set-aside delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The contract specifies performance at...
- The Defense Logistics Agency awarded a delivery order valued at $7,736.58 to AmerisourceBergen Drug Corp for Zepbound 10 mg/0.5 ml pen injections on November 4, 2025, with completion targeted for November 5, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The award represents a single purchase of a diabetes medication under the contractor's existing contract...
- The Defense Logistics Agency awarded a $3,094.84 delivery order to AmerisourceBergen Drug Corp (a subsidiary of parent company Cencora, Inc.) on January 23, 2026, for the supply of Zepbound 15 mg/0.5 mL pens. This firm fixed-price delivery order is scheduled for completion by January 26, 2026, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. The award was made on a competitive, non-set-aside basis and represents a task order under AmerisourceBergen's...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $4,821.96 by the Defense Logistics Agency on January 22, 2026, for the supply of Zepbound 15 mg/0.5 mL pens. The award was made on a firm fixed-price basis with no set-aside designation, indicating competition on a full and open basis. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $5,414.19 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injectable medication. The contract was issued on January 14, 2026, with an ultimate completion date of January 15, 2026, and represents a firm fixed-price purchase with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order under its parent...
- SPE2DR25D2018Indefinite Delivery Contract
- SPE2DR25D2018-SPE2DR26FZ1A9Delivery Order
The Defense Logistics Agency (DLA) awarded a $13,747.59 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen (0.5 mL), a diabetes and weight management medication. This firm fixed-price contract, awarded on January 29, 2026, is a non-set-aside competitive award with a completion date of January 30, 2026, and performance to be fulfilled from the contractor's facility in Conshohocken, Pennsylvania. The delivery order falls under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, valued at $999,999,999.00 through December 2026, which serves as a comprehensive global pharmaceutical support vehicle for military healthcare programs worldwide. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor and critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to supply a diverse range of pharmaceutical products and medical supplies across multiple therapeutic domains through open competition. Cencora, Inc. maintains the primary IDC with DLA Troop Support Medical valued at up to $999,999,999.00 through December 2031, enabling efficient fulfillment of essential pharmaceutical and medical commodities required by military treatment facilities and other federal medical institutions globally.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.7k | 1/28/26 |